Patiromer vs Sodium zirconium cyclosilicate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Gastrointestinal potassium binder · full Chronic Kidney Disease pipeline

Patiromer · Veltassa

Marketed by CSL Limited and partners

Phase 3 in Chronic Kidney DiseaseSmall molecule (ion-exchange polymer)
Partial signal

NCT01810939 · Phase 3 · completed

The study enrolled 243 participants and used single-blind treatment; Part A assessed patiromer without a concurrent comparator, while Part B randomized 107 patiromer responders to continued patiromer or placebo. Both primary serum-potassium comparisons favored patiromer with p<0.001, but serum potassium is a laboratory surrogate rather than a hard clinical or endoscopic endpoint.

Next expected readout: December 2026 · NCT06256991 (registry estimate)

Reported efficacy

Change in Serum Potassium From Part A Baseline to Part A Week 4; Change in Serum Potassium From Part B Baseline (Part B Baseline to Part B Week 4 or first local laboratory serum potassium < 3.8 mEq/L or ≥ 5.5 mEq/L): Change in Serum Potassium From Part A Baseline to Part A Week 4 (Part A Baseline to Part A Week 4): Part A Patiromer -1.01 mEq/L (Standard Error 0.031) (met)

Result source: NCT01810939

Sodium zirconium cyclosilicate · Lokelma

Marketed by AstraZeneca

Phase 3 in Chronic Kidney DiseaseSmall molecule (ion-exchange compound)
Partial signal

NCT05056727 · Phase 3 · terminated

This was a large, well-designed, randomized, quadruple-blind, placebo-controlled trial using an objective kidney-function measure as its primary endpoint, but neither of its two primary comparisons (total or chronic eGFR slope) showed a statistically significant difference between sodium zirconium cyclosilicate and placebo.

Next expected readout: December 2026 · NCT06578078 (registry estimate)

Reported efficacy

Total eGFR Slope (Coprimary Analysis #1) (Baseline (Maintenance phase) to visit 17 (week 69)); Chronic eGFR Slope (Coprimary Analysis #2) (12 weeks to visit 17 (week 69)): Total eGFR Slope (Coprimary Analysis #1) (Baseline (Maintenance phase) to visit 17 (week 69)): Maintenance Phase: SZC -5.2975 mL/min/(1.73 m2)/yr (95% CI -6.6854 to -3.9097) vs Maintenance Phase: Placebo -4.5622 mL/min/(1.73 m2)/yr (95% CI -5.9969 to -3.1275) (missed)

Result source: NCT05056727

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPatiromerSodium zirconium cyclosilicate
Kidney composite outcome—Not posted · NCT05136664—Not posted · NCT05004363
UACR, % change—Not posted · NCT05136664—Not posted · NCT05004363
eGFR slope—Not posted · NCT05136664—Not posted · NCT05004363
Haemoglobin, change—Not posted · NCT05136664—Not posted · NCT05004363

Kidney composite outcome

Patiromer
—Not posted · NCT05136664
Sodium zirconium cyclosilicate
—Not posted · NCT05004363

UACR, % change

Patiromer
—Not posted · NCT05136664
Sodium zirconium cyclosilicate
—Not posted · NCT05004363

eGFR slope

Patiromer
—Not posted · NCT05136664
Sodium zirconium cyclosilicate
—Not posted · NCT05004363

Haemoglobin, change

Patiromer
—Not posted · NCT05136664
Sodium zirconium cyclosilicate
—Not posted · NCT05004363
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Patiromer: 4 of 4 rows · Sodium zirconium cyclosilicate: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPatiromerSodium zirconium cyclosilicate
Dropout rate
9.9%Part A Patiromera
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 13 more results
—Part B Patiromer
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
5.9%
NCT03781089 · Phase 4 · registry result, not featured evidence
33.3%
NCT03183778 · Phase 4 · registry result, not featured evidence · combination
25%
NCT02933450 · Phase 4 · registry result, not featured evidence
3.7%
NCT03326583 · Phase 2 · registry result, not featured evidence
2%
NCT03071263 · Phase 2 · registry result, not featured evidence
24.3%8.4 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
46.7%33.6 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
32.4%25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
25%25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
31.1%16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
34.6%16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
11.1%
NCT01130597 · Phase 2 · registry result, not featured evidence
—b
NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3
show 4 more results
—
NCT05347693 · Phase 4 · registry result, not featured evidence
0%10 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
0%3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
0%0.3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4.1%Part A Patiromera
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 13 more results
—Part B Patiromer
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
—
NCT03781089 · Phase 4 · registry result, not featured evidence
—
NCT03183778 · Phase 4 · registry result, not featured evidence · combination
—
NCT02933450 · Phase 4 · registry result, not featured evidence
—
NCT03326583 · Phase 2 · registry result, not featured evidence
0.7%
NCT03071263 · Phase 2 · registry result, not featured evidence
5.4%8.4 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
6.7%33.6 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
9.5%25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
7.1%25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
2.7%16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
7.7%16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
6.3%
NCT01130597 · Phase 2 · registry result, not featured evidence
—b
NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3
show 4 more results
—
NCT05347693 · Phase 4 · registry result, not featured evidence
—10 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
—3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
—0.3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
Serious AEs
1.2%Part A Patiromera
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 13 more results
0%Part B Patiromer
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
11.8%
NCT03781089 · Phase 4 · registry result, not featured evidence
0%
NCT03183778 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02933450 · Phase 4 · registry result, not featured evidence
40.7%
NCT03326583 · Phase 2 · registry result, not featured evidence
0.7%
NCT03071263 · Phase 2 · registry result, not featured evidence
12.2%8.4 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
13.3%33.6 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
13.7%25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
17.9%25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
13.7%16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
23.1%16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
9.5%
NCT01130597 · Phase 2 · registry result, not featured evidence
18.4%b
NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3
show 4 more results
42.6%
NCT05347693 · Phase 4 · registry result, not featured evidence
0%10 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
0%3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
0%0.3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
constipation 10.7% (placebo 0%)
hypertension 1.6% (placebo 5.8%)
headache 0.8% (placebo 7.7%)
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 12 more results
constipation 3.6% (placebo 0%)
headache 3.6% (placebo 7.7%)
influenza 1.8% (placebo 5.8%)
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
bloody stools/diarrhea 5.9%
constipation 5.9%
emergency room visit due to shortness of breath 5.9%
NCT03781089 · Phase 4 · registry result, not featured evidence
hypoglycemia 20%
gi side effects 6.7%
NCT02933450 · Phase 4 · registry result, not featured evidence
constipation 0%
diarrhea 0%
hypomagnesemia 0%
NCT03326583 · Phase 2 · registry result, not featured evidence
renal impairment 8.8% (placebo 6.8%)
diarrhoea 6.1% (placebo 5.4%)
headache 6.1% (placebo 7.4%)
NCT03071263 · Phase 2 · registry result, not featured evidence
8.4 g/d
diarrhoea 8.1%
hypertension 6.8%
renal failure chronic 6.8%
NCT01371747 · Phase 2 · registry result, not featured evidence
33.6 g/d
renal failure chronic 20%
constipation 16.7%
hypomagnesaemia 16.7%
NCT01371747 · Phase 2 · registry result, not featured evidence
25.2 g/d
hypomagnesaemia 8.2%
anaemia 5.5%
constipation 5.5%
NCT01371747 · Phase 2 · registry result, not featured evidence
25.2 g/d
hypomagnesaemia 14.3%
renal failure chronic 10.7%
angina pectoris 7.1%
NCT01371747 · Phase 2 · registry result, not featured evidence
16.8 g/d
hypertension 9.6%
diarrhoea 6.8%
hypomagnesaemia 6.8%
NCT01371747 · Phase 2 · registry result, not featured evidence
16.8 g/d
hypertension 15.4%
diarrhoea 11.5%
cardiac failure chronic 7.7%
NCT01371747 · Phase 2 · registry result, not featured evidence
abdominal discomfort 6.3%
NCT01130597 · Phase 2 · registry result, not featured evidence
b
hypokalaemia 12.3% (placebo 0.3%)
hyperkalaemia 6.4% (placebo 26.2%)
hypertension 5% (placebo 3.7%)
NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3
show 4 more results
hyperkalaemia 17.6%
renal impairment 7.4%
cardiac failure 5.9%
NCT05347693 · Phase 4 · registry result, not featured evidence
10 g Three Times Daily
vomiting 12.5% (placebo 3.3%)
nausea 8.3% (placebo 3.3%)
urinary tract infection 8.3% (placebo 0%)
NCT01493024 · Phase 2 · registry result, not featured evidence
3 g Three Times Daily
aspartate aminotransferae increased 4.2% (placebo 0%)
constipation 4.2% (placebo 0%)
nausea 4.2% (placebo 3.3%)
NCT01493024 · Phase 2 · registry result, not featured evidence
0.3 g Three Times Daily
abdominal pain 8.3% (placebo 0%)
diarrhea 8.3% (placebo 0%)
abdominal tenderness 0% (placebo 3.3%)
NCT01493024 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 12 of these studies.
  2. bPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Patiromer

Serum Potassium in Target Range 100% (n=63) @ 8wk8.4 g/d
responder rate · % of participants
No placebo or comparator arm
NCT01371747 · Phase 2 · registry result, not featured evidence
show 24 more results
95.2% (n=63) @ 8wk8.4 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
86.3% (n=58) @ 52wk8.4 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
95.5% (n=22) @ 8wk33.6 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
77.3% (n=22) @ 8wk33.6 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
93.3% (n=20) @ 52wk33.6 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
98.4% (n=64) @ 8wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
95.8% (n=24) @ 8wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
81.3% (n=64) @ 8wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
91.7% (n=24) @ 8wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
88.9% (n=59) @ 52wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
89.5% (n=24) @ 52wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
100% (n=65) @ 8wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
91.7% (n=24) @ 8wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
90.8% (n=65) @ 8wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
79.2% (n=24) @ 8wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
81.6% (n=63) @ 52wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
86.7% (n=22) @ 52wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
76% (n=243) @ 4wk
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
90.5% (n=63) @ 8wk
NCT01130597 · Phase 2 · registry result, not featured evidence
96.7% (n=61) @ 4wk
NCT01130597 · Phase 2 · registry result, not featured evidence
93% (n=57) @ 8wk
NCT01130597 · Phase 2 · registry result, not featured evidence
78.7% (n=61) @ 4wk
NCT01130597 · Phase 2 · registry result, not featured evidence
86% (n=57) @ 8wk
NCT01130597 · Phase 2 · registry result, not featured evidence
84.1% (n=63) @ 8wk
NCT01130597 · Phase 2 · registry result, not featured evidence
Serum Potassium Ge 5.5 15% (n=55) vs 60% (n=52) placebo @ 8wk
responder rate · % of participants
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
Serum Potassium Ge 5.1 43% (n=55) vs 91% (n=52) placebo @ 8wk
responder rate · % of participants
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
Serum Potassium -1.01 mEq/L @ 4wk
absolute change · mEq/L
No placebo or comparator arm
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
Serum Potassium 0 vs 0.72 placebo mEq/L @ 4wk
absolute change · mEq/L
NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
Hyperkalemia Episode 13 count @ 4wk
event count · count
No placebo or comparator arm
NCT03781089 · Phase 4 · registry result, not featured evidence
Hyperkalemia Episode 0% (n=16) @ 4wk
event count · % of participants
No placebo or comparator arm
NCT03781089 · Phase 4 · registry result, not featured evidence
Serum Potassium -0.2 mg/dL @ 2wk
absolute change · mg/dL
No placebo or comparator arm
NCT03183778 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
0.7 mg/dL @ 4wk
NCT03183778 · Phase 4 · registry result, not featured evidence · combination
SBP -13 mmHg @ 2wk
absolute change · mmHg
No placebo or comparator arm
NCT03183778 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-14.9 mmHg @ 4wk
NCT03183778 · Phase 4 · registry result, not featured evidence · combination
DBP -5.5 mmHg @ 2wk
absolute change · mmHg
No placebo or comparator arm
NCT03183778 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-4.3 mmHg @ 4wk
NCT03183778 · Phase 4 · registry result, not featured evidence · combination
AOBP SBP -11.3 vs -11 placebo mmHg @ 12wk
absolute change · mmHg
NCT03071263 · Phase 2 · registry result, not featured evidence
show 1 more result
-11.3 vs -11.2 placebo mmHg @ 12wk
NCT03071263 · Phase 2 · registry result, not featured evidence
Serum Potassium Change Meq -0.35 mEq/L @ 4wk8.4 g/d
absolute change · mEq/L
No placebo or comparator arm
NCT01371747 · Phase 2 · registry result, not featured evidence
show 23 more results
-0.35 mEq/L @ 8wk8.4 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.26 mEq/L @ 0.43wk8.4 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
0.36 mEq/L8.4 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.92 mEq/L @ 4wk33.6 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.91 mEq/L @ 8wk33.6 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.53 mEq/L @ 0.43wk33.6 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
0.58 mEq/L33.6 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.55 mEq/L @ 4wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.97 mEq/L @ 4wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.54 mEq/L @ 8wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.95 mEq/L @ 8wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.31 mEq/L @ 0.43wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.59 mEq/L @ 0.43wk25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
0.3 mEq/L25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
0.39 mEq/L25.2 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.51 mEq/L @ 4wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.87 mEq/L @ 4wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.47 mEq/L @ 8wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.88 mEq/L @ 8wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.28 mEq/L @ 0.43wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
-0.65 mEq/L @ 0.43wk16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
0.22 mEq/L16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence
0.41 mEq/L16.8 g/d
NCT01371747 · Phase 2 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

Sodium zirconium cyclosilicate

eGFR Total Slope -5.2975 vs -4.5622 placebo mL @ 69wk
absolute value · mL
Maintenance
NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3
eGFR Chronic Slope -4.8705 vs -2.8285 placebo mL @ 69wk
absolute value · mL
NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3
Kidney Failure Composite 1.9% (n=359) vs 1.1% (n=354) placebo @ 97wk
event count · % of participants
Maintenance
NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3 · converted to % from 7 Participants as posted
RAASi Reduction 15.3% (n=359) vs 36.2% (n=354) placebo @ 97wk
event count · % of participants
Maintenance
NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3 · converted to % from 55 Participants as posted
UACR 1513.07 vs 1211.94 placebo mg @ 24wk
absolute change · mg
NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3
Serum Potassium in Target Range 30.9% (n=68) vs 36.2% (n=69) SoC @ 26wk
event count · % of participants
Response
NCT05347693 · Phase 4 · registry result, not featured evidence · converted to % from 21 Number of participants as posted
Time to First Hyperkalemia Composite Event 4.47 vs NA SoC months
time to event · months
NCT05347693 · Phase 4 · registry result, not featured evidence · converted to months from 136 days as posted
Time to First Hyperkalemia Hospitalization or ED Visit NA vs NA SoC months
time to event · months
NCT05347693 · Phase 4 · registry result, not featured evidence
show 1 more result
NA vs NA SoC months
NCT05347693 · Phase 4 · registry result, not featured evidence
Hyperkalemia-related Hospitalization or ED Event 0.7 vs 0.6 SoC count
event count · count
NCT05347693 · Phase 4 · registry result, not featured evidence
show 1 more result
0.1 vs 0.1 SoC count
NCT05347693 · Phase 4 · registry result, not featured evidence
Time to First RAASi Down-titration or Discontinuation NA vs NA SoC months
time to event · months
NCT05347693 · Phase 4 · registry result, not featured evidence
Serum Potassium Normalization 100% (n=24) vs 90% (n=30) placebo @ 0.29wk10 g Three Times Daily
responder rate · % of participants
NCT01493024 · Phase 2 · registry result, not featured evidence
show 8 more results
100% (n=24) vs 90% (n=30) placebo @ 0.43wk10 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
100% (n=24) vs 90% (n=30) placebo10 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
95.8% (n=24) vs 90% (n=30) placebo @ 0.29wk3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
95.8% (n=24) vs 90% (n=30) placebo @ 0.43wk3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
95.8% (n=24) vs 90% (n=30) placebo3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
75% (n=12) vs 90% (n=30) placebo @ 0.29wk0.3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
100% (n=12) vs 90% (n=30) placebo @ 0.43wk0.3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
75% (n=12) vs 90% (n=30) placebo0.3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
Serum Potassium Decrease 0.5 33.3% (n=24) vs 16.7% (n=30) placebo @ 0.29wk10 g Three Times Daily
responder rate · % of participants
NCT01493024 · Phase 2 · registry result, not featured evidence
show 5 more results
62.5% (n=24) vs 26.7% (n=30) placebo @ 0.43wk10 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
37.5% (n=24) vs 16.7% (n=30) placebo @ 0.29wk3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
41.7% (n=24) vs 26.7% (n=30) placebo @ 0.43wk3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
33.3% (n=12) vs 16.7% (n=30) placebo @ 0.29wk0.3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence
41.7% (n=12) vs 26.7% (n=30) placebo @ 0.43wk0.3 g Three Times Daily
NCT01493024 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Patiromer's landscape · Sodium zirconium cyclosilicate's landscape